<DOC>
	<DOCNO>NCT01289951</DOCNO>
	<brief_summary>Raltegravir first integrase inhibitor use human . It show highly efficacious well tolerated phase III clinical trial multidrug experienced human immunodeficiency virus ( HIV ) -infected patient , well initial therapy untreated patient . Pharmacokinetic study healthy adult subject indicate major mechanism clearance drug glucuronidation mediate UGT1A1 , minor contribution renal excretion unchanged parent compound . Unlike CYP-based metabolism , glucuronidation generally find relatively unaffected hepatic disease . A single dose pharmacokinetic study raltegravir patient mild moderate hepatic insufficiency ( Steigbigel et al . 2008 ) find clinically important effect drug pharmacokinetic profile , dosage adjustment necessary . The liver safety tolerability boost atazanavir ( ATV/r ) evaluate human immunodeficiency virus hepatitis C virus ( HIV/HCV ) coinfected patient advanced liver disease ( decompensated cirrhosis ) ( Hermida JM et al . 4th IAS : Sidney , 2007 ) . Similar Raltegravir , ATV also mainly metabolize conjugation UGT1A1 . There urgent need potent efficacious ARV drug clean safety liver profile even patient severe liver disease . The investigator hypothesize pharmacokinetics alter HIV/HCV patient advance ( Child-Pugh grade C ) cirrhosis histologic liver damage .</brief_summary>
	<brief_title>Pharmacokinetic Study Raltegravir Human Immunodeficiency Virus/Hepatitis C Virus ( HIV/VHC ) Coinfected Patients With Advanced ( Child-Pugh C ) Hepatic Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Adults , clinically stable HIV/HCV coinfected patient HAART control viremia ( &lt; 50 copies/ml ) least 6 month . HAART base boost protease inhibitor ( lopinavir , fosamprenavir darunavir ) . Hepatic Stability define absence new event descompensation ( ChildPugh score ) previous six week data progressive hepatic insufficiency . Liver biopsy perform previous year show liver damage ( F0F1 Metavir score ) elastometry result ≤ 6 Kpa , classify patient group B. Liver cirrhosis guide biopsy ( F4 Metavir score ) elastometry : result ≥ 14 Kpa , classify patient group A . Body mass index ( BMI ) range 1935 kg/m2 . HBV surface antigen positive . Clinical demonstration new descompensation event previous 6 week . Alcohol abuse average daily consumption &gt; 20g . Treatment boost atazanavir , saquinavir indinavir . Concomitant treatment phenytoin , phenobarbital rifampinor UGT1A1 inhibitor . Use investigational agent ( ART expand access ) within 90 day randomization . Active previous HCV treatment Ribavirin /or Peginterferon sustain virological response achieve . Women take oral contraceptive Pregnancy lactancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>VHC</keyword>
	<keyword>Advanced hepatic cirrhosis</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Raltegravir</keyword>
</DOC>